Most companies approve big CapEx more rigorously than they ever review it afterward.
Large investments usually clear the same internal hurdles: IRR above the hurdle rate, acceptable payback period, plausible strategic rationale. The investment gets approved. And then, quietly, value fails to appear.
The wrong unit of analysis
Markets do not value projects. They value companies.
A project can show an attractive IRR and still dilute capital efficiency at the company level — if the incremental return on capital deployed is not strong enough to sustain or improve the firm's economic spread.
The relevant measure is not project IRR alone. It is:
Incremental ROIC = ΔNOPAT / ΔIC
And the value creation test is:
Value creation ≈ (ROIC − WACC) × ΔIC
Capital creates value only when incremental deployment preserves a positive spread. A project that clears IRR but compresses company-level ROIC is not growth. It is capital deployed without improving firm-wide economics.
"Growth" CapEx is often not growth
Companies routinely label defensive spending as growth investment. But much of what is called growth CapEx is simply the cost of staying in the game — defending market share, retaining key customers, responding to competitors, avoiding strategic retreat.
From a management perspective, such investment may feel unavoidable. From a valuation perspective, capital deployed to preserve position rather than improve future economics is not value-creative, regardless of what it is called.
This is why management approves investments the market greets with skepticism. Management sees strategic necessity. The market sees weak incremental returns.
Incremental ROIC declines as capital scales
There is a compounding problem: incremental ROIC rarely stays flat as more capital is deployed.
The best projects are executed first. What follows is weaker project quality, higher execution complexity, more overhead, slower ramp-ups, and greater cannibalization. The same dynamic appears in M&A — even a sound target delivers deteriorating returns if the purchase price is too high.
Capital allocation does not get easier with scale. It gets harder. Returns compress either because operating economics weaken, or because the price paid becomes too expensive.